VivoSeq
Oncology

Biliary Tract Carcinoma

5

Pipeline Programs↗

6

Active Trials↗

5

Companies Involved↗

Biliary Tract Carcinoma is an early-stage landscape with 5 programs across 5 companies. The most active players are Arcus Biosciences, AstraZeneca, McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc..

Intelligence

Pipeline Metrics

Competitive Density

33/100

Pipeline Velocity

0/100

Mech. Concentration

33/100

Completion Rate

60/100

Attrition Rate

7/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Arcus Biosciences logo

Arcus Biosciences

2 programs

Phase 2AstraZeneca logo

AstraZeneca

1 program

Phase 2M

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

1 program

Phase 2Johnson & Johnson logo

Johnson & Johnson

1 program

Phase 2Eli Lilly logo

Eli Lilly

0 programs

Preclinical

Pipeline

Programs by Phase

Analysis

Modality Breakdown

80%

Small molecule

4 of 5 classified programs — the dominant modality here.

20%ALL OTHERSMonoclonal antibody120%

Small molecule leads; the ring shows all 5 classified programs, each share of the total. Modality classified for 100% of 5 pipeline programs.

Analysis

Trial Status

14

clinical trials

Unknown status3 · 21%
Not yet recruiting3 · 21%
Completed3 · 21%
Active, not recruiting2 · 14%
Suspended1 · 7%
Terminated1 · 7%
Other1 · 7%

Clinical Trials

Trial Activity

14 trials

A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC)
Recruiting·National Cancer Institute (NCI)·Phase 1/2·NCT05849480·60 enrolled
Study of Gemcitabine, Cisplatin, Quemliclustat (AB680) and Zimberelimab (AB122) During First-line Treatment of Advanced Biliary Tract Cancers (QUIC)
Active, not recruiting·—·Phase 2·NCT06048133·33 enrolled
A Randomized Phase II Trial of MEK Inhibitor Selumetinib (AZD6244) Combined Continuously or Sequentially With Cisplatin/Gemcitabine (CIS/GEM) Versus CIS/GEM Alone in Patients With Advanced Biliary Cancer
Active, not recruiting·UUniversity Health Network, Toronto·Phase 2·NCT02151084·57 enrolled
Circulating Tumor DNA Guided Adjuvant Chemotherapy for Biliary Tract Carcinoma
Not yet recruiting·SShanghai East Hospital·N/A·NCT06171321·94 enrolled
Irinotecan Hydrochloride Liposome Combined With Capecitabine and Lenvatinib in Patients With Biliary Tract Carcinoma
Not yet recruiting·—·N/A·NCT06463548·30 enrolled
Pemigatinib Combined With Durvalumab for Previously Treated Biliary Tract Carcinoma
Not yet recruiting·—·Phase 2·NCT06530823·38 enrolled
Study of Surufatinib as Second-line Treatment in Patients With Biliary Tract Carcinoma
Completed·HHutchison Medipharma Limited·Phase 2·NCT02966821·39 enrolled
Trial of Gemcitabine and Cisplatin in Patients With Inoperable Biliary Tract Carcinomas
Completed·Eli Lilly logoEli Lilly·Phase 2·NCT00490399·39 enrolled
Study of Hepatic Arterial Infusion to Treat Biliary Tract Carcinomas
Completed·PPeking University·Phase 2·NCT01572324·37 enrolled
SBRT Sequential Surufatinib Combined With Immunotherapy for Biliary Tract Carcinoma
Suspended·ZZhejiang Cancer Hospital·Phase 2·NCT06199882·34 enrolled
Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas
Terminated·—·Phase 2·NCT00532441·25 enrolled
A Study of Capecitabine Versus S-1 as Adjuvant Therapy in Patients With Biliary Tract Carcinoma After Surgical Resection
Unknown status·FFudan University·N/A·NCT04856761·160 enrolled
A Real-world Study of the Safety and Efficacy of Surufatinib in the Treatment of Biliary Tract Carcinoma
Unknown status·QQilu Hospital of Shandong University·N/A·NCT05064852·200 enrolled
A Trial Evaluating Surufatinib Efficacy and Safety in Biliary Tract Carcinoma Patients
Unknown status·HHutchison Medipharma Limited·Phase 2/3·NCT03873532·298 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)